Nasdaq

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Dose-proportional oral bioavailability without clinical signs, including those associated with hallucinogenic compounds, was demonstrated in rat and dog pharmacokinetic (PK) studies while significant ...
Medscape

Divalproex to Divalproex Extended Release Conversion

Objective: Divalproex extended release (ER) tablets have lower bioavailability than conventional divalproex tablets. Objectives were to provide dose-increment justification for conversion of a patient ...
News Medical

Validation criteria for a jejunum-hepatocyte dual-organ MPS for drug ADME studies

This article is based on a poster originally authored by Yassen Abbas, Hailey Sze, Christiana Skarlatopoulou, Ashley A. Spreen, Elizabeth M. Boazak, William R. Thelin, and Tomasz Kostrzewski which was ...
Business Wire

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small molecule ...